EUVIMEDEUVIMED entdecken
Open Access

A CEBPB/IL-1β/TNF-α feedback loop drives drug resistance to venetoclax and MDM2 inhibitors in monocytic leukemia

Basil Allen, Daniel Bottomly, Thomas Köhnke, Anthony Wang iD, Hsin-Yun Lin, Kara Johnson, Isabel Kenna, Anastatia Streltsova, Emma Martin, Reid Chen, Lindsey Savoy, Nicola Long iD und 18 weitere

Blood · 2025

DOI: 10.1182/blood.2024028239 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, 2025. Verfasst von Basil Allen und 29 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, OR. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-mdm2, Sulfonamides, Bridged Bicyclo Compounds, Heterocyclic, Tumor Necrosis Factor-alpha. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Abstrat MDM2 inhibitors are promising therapeutics for acute myeloid leukemia (AML) with wild-type TP53. Through an integrated analysis of functional genomic data from primary patient samples, we found that an MDM2 inhibitor, idasanutlin, like venetoclax, is ineffective against monocytic leukemia (French-American-British [FAB] subtype M4/M5). To dissect the underlying resistance mechanisms, we explored both intrinsic and extrinsic factors. We found that monocytic leukemia cells express elevated levels of CEBPB, which promote monocytic differentiation, suppress CASP3 and CASP6, and upregulate MCL1, BCL2A1, and the interleukin (IL-1)/tumor necrosis factor alpha (TNF-α)/NF-κB pathway members, thereby conferring drug resistance to a broad range of MDM2 inhibitors, BH3 mimetics, and venetoclax combinations. In addition, aberrant monocytes in M4/M5 leukemia produce elevated levels of IL-1 and TNF-α, which promote monocytic differentiation and upregulate inflammatory cytokines and receptors, thereby extrinsically protecting leukemia blasts from venetoclax and MDM2 inhibition. Interestingly, IL-1β and TNF-α only increase CEBPB levels and protect M4/M5 cells from these drugs but not M0/M1 leukemia cells. Treatment with venetoclax and idasanutlin induces compensatory upregulation of CEBPB and the IL-1/TNF-α/NF-κB pathway independent of the FAB subtype, indicating drug-induced compensatory protection mechanisms. The combination of venetoclax or idasanutlin with inhibitors that block the IL-1/TNF-α pathway demonstrates synergistic cytotoxicity in M4/M5 AML. As such, we uncovered a targetable positive feedback loop that involves CEBPB, IL-1/TNF-α, and monocyte differentiation in M4/M5 leukemia and promotes both intrinsic and extrinsic drug resistance and drug-induced protection against venetoclax and MDM2 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-mdm2SulfonamidesBridged Bicyclo Compounds, HeterocyclicTumor Necrosis Factor-alphaDrug Resistance, NeoplasmInterleukin-1betaCCAAT-Enhancer-Binding Protein-betaLeukemia, Monocytic, AcuteHumansSignal TransductionCell Line, TumorAntineoplastic AgentsMonocytes

Substanzen

Proto-Oncogene Proteins c-mdm2venetoclaxSulfonamidesBridged Bicyclo Compounds, HeterocyclicMDM2 protein, humanTumor Necrosis Factor-alphaInterleukin-1betaCCAAT-Enhancer-Binding Protein-betaIL1B protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
  • Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
  • Division of Hematology, Department of Medicine, Cancer Institute and Institute of Stem Cell Biology and Regenerative Medicine, Stanford, CA.
  • Department of Cell, Developmental and Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
  • Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
  • Massively Parallel Sequencing Shared Resource, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.

ORCID-Profile: Anthony Wang, Nicola Long, Stephen E Kurtz, Christopher A Eide, Tingting Liu, Paul D Piehowski, Sara J C Gosline, Bill H Chang, Michelle Barton, Brian J Druker, Shannon K McWeeney, Jeffrey W Tyner, Haijiao Zhang

Förderung

  • NCI NIH HHS

Zitieren

APA

Allen, B., Bottomly, D., Köhnke, T., Wang, A., Lin, H. Y., Johnson, K., Kenna, I., Streltsova, A., Martin, E., Chen, R., Savoy, L., Long, N., Ryabinin, P., Kurtz, S. E., Eide, C. A., Carlos, A., Kaempf, A., Liu, T., Tognon, C., …, & Zhang, H. (2025). A CEBPB/IL-1β/TNF-α feedback loop drives drug resistance to venetoclax and MDM2 inhibitors in monocytic leukemia. Blood. https://doi.org/10.1182/blood.2024028239

Vancouver

Allen B, Bottomly D, Köhnke T, Wang A, Lin HY, Johnson K, et al. A CEBPB/IL-1β/TNF-α feedback loop drives drug resistance to venetoclax and MDM2 inhibitors in monocytic leukemia. Blood. 2025. doi:10.1182/blood.2024028239

BibTeX
@article{Allen2025,
  author = {Allen, Basil and Bottomly, Daniel and Köhnke, Thomas and Wang, Anthony and Lin, Hsin-Yun and Johnson, Kara and Kenna, Isabel and Streltsova, Anastatia and Martin, Emma and Chen, Reid and Savoy, Lindsey and Long, Nicola and Ryabinin, Peter and Kurtz, Stephen E and Eide, Christopher A and Carlos, Amy and Kaempf, Andy and Liu, Tingting and Tognon, Cristina and Searles, Robert and Piehowski, Paul D and Gosline, Sara J C and Agarwal, Anupriya and Chang, Bill H and Barton, Michelle and Druker, Brian J and McWeeney, Shannon K and Majeti, Ravindra and Tyner, Jeffrey W and Zhang, Haijiao},
  title = {A CEBPB/IL-1β/TNF-α feedback loop drives drug resistance to venetoclax and MDM2 inhibitors in monocytic leukemia},
  journal = {Blood},
  year = {2025},
  doi = {10.1182/blood.2024028239}
}
Kostenlos starten →